



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

HE the Ambassador
Permanent Representation of Estonia
Rue Guimard 11-13
B-1040 Bruxelles
BELGIUM

19 November 2025
EMA/367065/2025
Executive Director

Your Excellency,

Subject: Nomination of representatives in the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency

In accordance with Regulation (EC) No 726/2004, members and alternates of the European Medicines Agency's Management Board and scientific committees are nominated for a three-year mandate by EU member states and EEA-EFTA countries.

The three-year mandate of the representative listed below is due to expire. I, therefore, invite you to nominate representative for a new three-year mandate starting from the date indicated below. In case you are nominating new representative and a different start date for the mandate is envisaged, please inform me accordingly.

- Edward Laane Alternate 26 March 2026

I would like to emphasize the importance of a timely nomination of a committee member to ensure the continuous representation of your Member State in the Committee. To avoid a vacant committee member position when an alternate position is already filled, you may consider nominating the alternate (temporarily) as member.

Please also inform me if you intend to keep the position temporarily vacant. If no nomination is received, the position will be considered temporarily vacant until a nomination is received.

In making your nominations, please note that the Agency's Management Board has determined that members of scientific committees should meet conditions concerning their declarations of interests as described in the Policy on the handling of competing interests of scientific committees' members and experts. This policy can be found on the EMA website.

I would like to draw your attention to the attached Annex B, which lists the recommended criteria for experience and expertise of the Committee members and alternates for consideration when nominating a new representative.

As agreed with the network of the Heads of Medicines Agencies in order to address the increasing complexity in scientific developments related to the Committee's activities, the current expertise of the Committee and the expertise required for upcoming procedures are monitored. It would be appreciated if the following specific areas of expertise that were identified as desirable for the current and upcoming work of the Committee, could be taken into consideration when nominating a new



representative, subject to the availability of such expertise to the relevant competent authority in your country:

- Infectious diseases (e.g. COVID-19)
- Oncology
- Neurology
- Ophthalmology
- Clinical pharmacokinetics

An overview of the current composition of the Committee and the expertise of its members is attached for your information.

Please address the nomination to my attention at Executive.Director@ema.europa.eu (with copy to Nominations@ema.europa.eu), indicating full contact details for the nominee and the start date of the mandate, together with any additional information you believe may assist this nomination. In case you already provided me with your nomination, I kindly ask you to disregard this correspondence.

Yours faithfully,

Emer Cooke
Executive Director

Encs:
Annex B
Current committee composition and expertise